More Insight Into Anti-Interleukins

Miguel Regueiro, MD

Professor of Medicine
Chair of the Digestive Disease & Surgery Institute
Cleveland Clinic, Cleveland

This month’s report focuses on the anti-interleukin treatments for inflammatory bowel disease, specifically those that target interleukin 12 and/or interleukin 23.

The first study compares clinical and endoscopic remission rates when using risankizumab (Skyrizi, AbbVie) or ustekinumab (Stelara, Janssen) for treating people